Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

被引:65
作者
Abdelmoneim, A. S. [1 ]
Eurich, D. T. [2 ]
Light, P. E. [3 ]
Senior, P. A. [4 ]
Seubert, J. M. [1 ,3 ]
Makowsky, M. J. [1 ]
Simpson, S. H. [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 1C9, Canada
[2] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 1C9, Canada
[3] Univ Alberta, Fac Med & Dent, Dept Pharmacol, Edmonton, AB T6G 1C9, Canada
[4] Univ Alberta, Fac Med & Dent, Dept Med, Edmonton, AB T6G 1C9, Canada
关键词
cardiovascular disease; sulphonylureas; TYPE-2; DIABETES-MELLITUS; ACUTE MYOCARDIAL-INFARCTION; ORAL HYPOGLYCEMIC AGENTS; ALL-CAUSE MORTALITY; K-ATP CHANNELS; VASCULAR COMPLICATIONS; POTASSIUM CHANNELS; CONTROLLED-TRIALS; GLUCOSE CONTROL; DRUGS INCREASE;
D O I
10.1111/dom.12456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
More than 40 years after publication of the University Group Diabetes Program trial, the cardiovascular safety of sulphonylureas is still contentious. Although several hypotheses linking sulphonylureas to adverse cardiovascular effects exist, none provide conclusive evidence. Adding to the controversy, current clinical trials and observational studies provide inconsistent, and sometimes conflicting, evidence for the cardiovascular effects of sulphonylureas. Overall, observational evidence suggests that an increased risk of adverse cardiovascular outcomes is associated with sulphonylureas; however, these data may be subject to residual confounding and bias. Although evidence from randomized controlled trials has suggested a neutral effect, the majority of these studies were not specifically designed to assess the effect of sulphonylureas on adverse cardiovascular event risk. Current ongoing large clinical trials may provide some clarity on the cardiovascular safety of sulphonylureas, but the results are not expected for several years. With the continued uncertainties concerning the cardiovascular safety of all antidiabetic drugs, a clear answer with regard to sulphonylureas is warranted. The objectives of the present article were to provide an overview of the controversy surrounding sulphonylurea-related cardiovascular effects, to discuss the limitations of the current literature, and to provide recommendations for future studies aiming to elucidate the true relationship between sulphonylureas and adverse cardiovascular effects in people with type 2 diabetes.
引用
收藏
页码:523 / 532
页数:10
相关论文
共 103 条
[81]   The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis [J].
Schopman, J. E. ;
Simon, A. C. R. ;
Hoefnagel, S. J. M. ;
Hoekstra, J. B. L. ;
Scholten, R. J. P. M. ;
Holleman, F. .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (01) :11-22
[82]   Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study [J].
Schramm, Tina Ken ;
Gislason, Gunnar Hilmar ;
Vaag, Allan ;
Rasmussen, Jeppe Norgaard ;
Folke, Fredrik ;
Hansen, Morten Lock ;
Fosbol, Emil Loldrup ;
Kober, Lars ;
Norgaard, Mette Lykke ;
Madsen, Mette ;
Hansen, Peter Riis ;
Torp-Pedersen, Christian .
EUROPEAN HEART JOURNAL, 2011, 32 (15) :1900-1908
[83]   INVOLVEMENT OF ACTIVATION OF ATP-DEPENDENT POTASSIUM CHANNELS IN ISCHEMIC PRECONDITIONING IN SWINE [J].
SCHULZ, R ;
ROSE, J ;
HEUSCH, G .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1994, 267 (04) :H1341-H1352
[84]   The UGDP controversy - thirty-four years of contentious ambiguity laid to rest [J].
Schwartz, TB ;
Meinert, CL .
PERSPECTIVES IN BIOLOGY AND MEDICINE, 2004, 47 (04) :564-574
[85]   SUMMARY OF CRITICISMS OF FINDINGS AND CONCLUSIONS OF UNIVERSITY GROUP DIABETES PROGRAM (UGDP) [J].
SELTZER, HS .
DIABETES, 1972, 21 (09) :976-&
[86]   Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review [J].
Selvin, Elizabeth ;
Bolen, Shari ;
Yeh, Hsin-Chieh ;
Wiley, Ciystal ;
Wilson, Lisa M. ;
Marinopoulos, Spyridon S. ;
Feldman, Leonard ;
Vassy, Jason ;
Wilson, Renee ;
Bass, Eric B. ;
Brancati, Frederick L. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (19) :2070-2080
[87]   Mortality risk among sulfonylureas: a systematic review and network meta-analysis [J].
Simpson, Scot H. ;
Lee, Jayson ;
Choi, Sabina ;
Vandermeer, Ben ;
Abdelmoneim, Ahmed S. ;
Featherstone, Travis R. .
LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (01) :43-51
[88]   Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study [J].
Simpson, SH ;
Majumdar, SR ;
Tsuyuki, RT ;
Eurich, DT ;
Johnson, JA .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (02) :169-174
[89]   Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies [J].
Stricker, B. H. Ch. ;
Stijnen, T. .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2010, 25 (04) :245-251
[90]   Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution-A Simulation Study [J].
Stuermer, Til ;
Rothman, Kenneth J. ;
Avorn, Jerry ;
Glynn, Robert J. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 172 (07) :843-854